DrugPatentWatch Database Preview
Drugs in Development Information for AZD-6280
What is the drug development status for AZD-6280?
AZD-6280 is an investigational drug.
There have been 30 clinical trials for AZD-6280.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2006.
The most common disease conditions in clinical trials are Adenocarcinoma, Ovarian Neoplasms, and Small Cell Lung Carcinoma. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Samsung Medical Center.
Summary for AZD-6280
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 7 |
| WIPO Patent Applications | 2 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2006-03-01) |
| Vendors | 4 |
Recent Clinical Trials for AZD-6280
| Title | Sponsor | Phase |
|---|---|---|
| Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | National Cancer Institute (NCI) | Phase 2 |
| Adavosertib With or Without Olaparib in Treating Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | M.D. Anderson Cancer Center | Phase 2 |
| Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian Cancer | AstraZeneca | Phase 2 |
Clinical Trial Summary for AZD-6280
Top disease conditions for AZD-6280
Top clinical trial sponsors for AZD-6280
US Patents for AZD-6280
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
